Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 3 OTHER_GOV 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Lymphoid 2 Gynecologic 2 Dermatologic 2 Breast 2 Plasma cell 1 Other solid neoplasm 1 Genitourinary 1 Gastrointestinal 1

Conditions

Colorectal Neoplasms 1 Colonic Neoplasms 1

Interventions

Gemcitabine 302 Fluorouracil 296 Oxaliplatin 269 Bevacizumab 267 Capecitabine 233 Leucovorin 229 pembrolizumab 215 Irinotecan 185 Cisplatin 142 Cetuximab 142 Nivolumab 131 Paclitaxel 117 130-nm albumin-bound paclitaxel 117 Sorafenib 86 Albumin-Bound Paclitaxel 75 Docetaxel 65 regorafenib 64 atezolizumab 64 IFL protocol 61 Folfox protocol 61 Trastuzumab 55 Panitumumab 47 durvalumab 46 Ramucirumab 43 Injections 43 Sunitinib 41 Drug Therapy 41 Carboplatin 40 trifluridine tipiracil drug combination 38 lenvatinib 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Drug Evaluation × Gastrointestinal × Clear all

NCT05189171 2024-06-28

MODEL-CRC

Xilis, Inc.

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡